δ -tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxia

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Ananthula, Suryatheja ^a   Parajuli, Parash ^a   Behery, Fathy A ^a   Alayoubi, Alaadin Y ^a   Nazzal, Sami ^a   El Sayed, Khalid ^a   Sylvester, Paul W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (6,8 DIMETHYL 8 (4,8,12 TRIMETHYLTRIDECA 3,7,11 TRIENYL) 9,10 DIHYDROCHROMENO[5,6 E][1,3]OXAZIN 2(1H,3H,8H) YL)DODECAN 1 OL; COBALT CHLORIDE; EUKARYOTIC INITIATION FACTOR 4E1; GAMMA TOCOTRIENOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXAZINE DERIVATIVE; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; ALPHA TOCOPHEROL; COBALT; HIF1A PROTEIN, MOUSE; TOCOTRIENOL, DELTA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER SURVIVAL; CELL HYPOXIA; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SOLID TUMOR; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; MAMMARY NEOPLASMS, ANIMAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; COBALT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY NEOPLASMS, ANIMAL; MICE; SIGNAL TRANSDUCTION; VITAMIN E;

EID: 84929051891     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/285752     Document Type: Article

References (47)

1. L. Holmgren, "Antiangiogenesis restricted tumor dormancy, " Cancer and Metastasis Reviews, vol. 15, no. 2, pp. 241-245, 1996.
2. Q. Ke and M. Costa, "Hypoxia-inducible factor-1 (HIF-1), " Molecular Pharmacology, vol. 70, no. 5, pp. 1469-1480, 2006.
3. G. L. Wang, B. H. Jiang, E. A. Rue, and G. L. Semenza, "Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, " Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 12, pp. 5510-5514, 1995.
4. G. L. Semenza, "Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1, " Annual Review of Cell and Developmental Biology, vol. 15, pp. 551-578, 1999.
5. G. L. Semenza, "HIF-1: using two hands to flip the angiogenic switch, " Cancer and Metastasis Reviews, vol. 19, no. 1-2, pp. 59-65, 2000.
6. G. L. Semenza, "HIF-1 and tumor progression: pathophysiology and therapeutics, " Trends inMolecularMedicine, vol. 8, no. 4, pp. S62-S67, 2002.
7. R. K. Bruick and S. L. McKnight, "A conserved family of prolyl-4-hydroxylases that modify HIF, " Science, vol. 294, no. 5545, pp. 1337-1340, 2001.
8. M. Ivan, K. Kondo, H. Yang et al., "HIFα targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing, " Science, vol. 292, no. 5516, pp. 464-468, 2001.
9. G. L. Semenza, "HIF-1, O2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus, " Cell, vol. 107, no. 1, pp. 1-3, 2001.
10. A. L. Harris and K. L. Talks, "Current status of antiangiogenic factors, " British Journal of Haematology, vol. 109, no. 3, pp. 477-489, 2000.
11. K. Mizokami, Y. Kakeji, S. Oda et al., "Clinicopathologic significance of hypoxia-inducible factor 1α overexpression in gastric carcinomas, " Journal of Surgical Oncology, vol. 94, no. 2, pp. 149-154, 2006.
12. J. Josko, B. Gwozdz, H. Jedrzejowska-Szypulka, and S. Hendryk, "Vascular endothelial growth factor (VEGF) and its effect on angiogenesis, " Medical Science Monitor, vol. 6, no. 5, pp. 1047-1052, 2000.
13. M. Miyazawa, M. Yasuda, M. Fujita et al., "Therapeutic strategy targeting themTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma, " Pathology International, vol. 59, no. 1, pp. 19-27, 2009.
14. B. E. Johnson, D. Jackman, and P. A. Janne, "Rationale for a phase I trial of erlotinibandthemammaliantargetof rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer, " Clinical Cancer Research, vol. 13, pp. S4628-S4631, 2007.
15. B. T. Nave, D. M. Ouwens, D. J. Withers, D. R. Alessi, and P. R. Shepherd, "Mammalian target of rapamycin is a direct target for protein kinase B: Identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation, " Biochemical Journal, vol. 344, part 2, pp. 427-431, 1999.
16. J. D. Richter and N. Sonenberg, "Regulation of cap-dependent translation by eIF4E inhibitory proteins, " Nature, vol. 433, no. 7025, pp. 477-480, 2005.
17. C. Mayer, J. Zhao, X. Yuan, and I. Grummt, "mTOR-dependent activation of the transcription factor TIF-IAlinks rRNAsynthesis to nutrient availability, " Genes and Development, vol. 18, no. 4, pp. 423-434, 2004.
18. M. Laplante and D. M. Sabatini, "mTOR signaling at a glance, " Journal of Cell Science, vol. 122, no. 20, pp. 3589-3594, 2009.
19. D. E. Richard, E. Berra, E. Gothie, D. Roux, and J. Pouyssegur, "p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-reducible factor (HIF-1α) and enhance the transcriptional activity ofHIF-1, "The Journal of Biological Chemistry, vol. 274, no. 46, pp. 32631-32637, 1999.
20. B. S. McIntyre, K. P. Briski, A. Gapor, and P. W. Sylvester, "Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells, " Proceedings of the Society for Experimental Biology and Medicine, vol. 224, pp. 292-301, 2000.
21. S. Shin-Kang, V. P. Ramsauer, J. Lightner et al., "Tocotrienols inhibitAKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway, " Free Radical Biology and Medicine, vol. 51, no. 6, pp. 1164-1174, 2011.
22. A. Barve, T. O. Khor, K. Reuhl, B. Reddy, H. Newmark, and A. Kong, "Mixed tocotrienols inhibit prostate carcinogenesis in TRAMPmice, "Nutrition and Cancer, vol. 62, no. 6, pp. 789-794, 2010.
23. F. A. Behery, M. R. Akl, S. Ananthula, P. Parajuli, P. W. Sylvester, and K. A. El Sayed, "Optimization of tocotrienols as antiproliferative and antimigratory leads, " European Journal of Medicinal Chemistry, vol. 59, pp. 329-341, 2013.
24. S. Ananthula, P. Parajuli, and F. A. Behery, "Oxazine derivatives of γ-and δ-tocotrienol display enhanced anticancer activity in vivo, " Anticancer Research, vol. 34, pp. 2715-2726, 2014.
25. Y. Huang, K.-M. Du, Z.-H. Xue et al., "Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α, " Leukemia, vol. 17, no. 11, pp. 2065-2073, 2003.
26. J. Y. Jung and W. J. Kim, "Involvement of mitochondrial-and Fas-mediated dual mechanism in CoCl2-induced apoptosis of rat PC12 cells, " Neuroscience Letters, vol. 371, no. 2-3, pp. 85-90, 2004.
27. L. W. Anderson, K. G. Danielson, and H. L. Hosick, "New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue, " In Vitro, vol. 15, no. 11, pp. 841-843, 1979.
28. K. G. Danielson, L. W. Anderson, and H. L. Hosick, "Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo, " Cancer Research, vol. 40, no. 6, pp. 1812-1819, 1980.
29. S. Shah, A. Gapor, and P. W. Sylvester, "Role of caspase-8 activation in mediating vitamin E-induced apoptosis inmurine mammary cancer cells, " Nutrition and Cancer, vol. 45, no. 2, pp. 236-246, 2003.
30. S. V. Bachawal, V. B. Wali, and P. W. Sylvester, "Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses STAT and Akt signaling inmurinemammary tumor cells, " Anticancer Research, vol. 30, no. 2, pp. 429-437, 2010.
31. M. Jumaa and B. W. Muller, "Development of a novel parenteral formulation for tetrazepam using a lipid emulsion, " Drug Development and Industrial Pharmacy, vol. 27, no. 10, pp. 1115-1121, 2001.
32. A. Alayoubi, S. Kanthala, S. D. Satyanarayanajois, J. F. Anderson, P. W. Sylvester, and S. Nazzal, "Stability and in vitro antiproliferative activity of bioactive "Vitamin E" fortified parenteral lipid emulsions, " Colloids and Surfaces B: Biointerfaces, vol. 103, pp. 23-30, 2013.
33. A. Alayoubi, M. Nazzal, P. W. Sylvester, and S. Nazzal, ""Vitamin E" fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters, " Drug Development and Industrial Pharmacy, vol. 39, no. 2, pp. 363-373, 2013.
34. P. W. Sylvester, "Vitamin E-induced apoptosis in mouse mammary tumors, " in New Cell Apoptosis Research, R. G. Valentino, Ed., pp. 53-68, Nova Science, New York, NY, USA, 2007.
35. U. K. Laemmli, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4, " Nature, vol. 227, no. 5259, pp. 680-685, 1970.
36. H. Towbin, T. Staehelin, and J. Gordon, "Electrophoretic transfer of proteins frompolyacrylamide gels to nitrocellulose sheets: procedure and some applications, " Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 9, pp. 4350-4354, 1979.
37. M. Hockel and P. Vaupel, "Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects, " Journal of the National Cancer Institute, vol. 93, no. 4, pp. 266-276, 2001.
38. A. Marusyk, V. Almendro, and K. Polyak, "Intra-tumour heterogeneity: a looking glass for cancer?" Nature Reviews Cancer, vol. 12, no. 5, pp. 323-334, 2012.
39. J. Folkman, E. Merler, C. Abernathy, and G. Williams, "Isolation of a tumor factor responsible or angiogenesis, " Journal of Experimental Medicine, vol. 133, no. 2, pp. 275-288, 1971.
40. D. Shweiki, A. Itin, D. Soffer, and E. Keshet, "Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis, " Nature, vol. 359, no. 6398, pp. 843-845, 1992.
41. P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe, "Activation of the HIF pathway in cancer, " Current Opinion in Genetics and Development, vol. 11, no. 3, pp. 293-299, 2001.
42. E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza, "HER2 (neu) signaling increases the rate of hypoxiainducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, " Molecular and Cellular Biology, vol. 21, no. 12, pp. 3995-4004, 2001.
43. B.-H. Jiang, G. Jiang, J. Z. Zheng, Z. Lu, T. Hunter, and P. K. Vogt, "Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1, " CellGrowth andDifferentiation, vol. 12, no. 7, pp. 363-369, 2001.
44. S. C. Land and A. R. Tee, "Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif, " The Journal of Biological Chemistry, vol. 282, no. 28, pp. 20534-20543, 2007.
45. C. C. Hudson, M. Liu, G. G. Chiang et al., "Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin, " Molecular and Cellular Biology, vol. 22, no. 20, pp. 7004-7014, 2002.
46. T. Van Den Beucken, M. Koritzinsky, and B. G. Wouters, "Translational control of gene expression during hypoxia, " Cancer Biology and Therapy, vol. 5, no. 7, pp. 749-755, 2006.
47. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak, "Vascular endothelial growth factor (VEGF) and its receptors, " The FASEB Journal, vol. 13, no. 1, pp. 9-22, 1999.